MedTrace Logo

CASTRO1 - Study on CRP Apheresis After Ischemic Stroke

NCT04417231 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2023-05-18

No results posted yet for this study

Summary

CASTRO1 is a study to investigate the reduction of C-reactive protein (CRP) by therapeutic apheresis (CRP-apheresis) in patients after primary treatment of ischemic stroke.

The term therapeutic apheresis commonly refers to medical procedures, where pathogenic constituents are being removed from the circulating blood. Elimination is performed by adsorbers outside the body in an extracorporeal circulation. For removal of the pathogenic substances the plasma is separated from the blood (circulation) to pass the adsorber. The purified plasma is merged with the solid blood components thereafter and returned to the patient.

The adsorber "PentraSorb® CRP" used for CRP apheresis is CE-certified. It is designated to the selective depletion of C-reactive protein from human blood.

Conditions

  • Stroke, Ischemic

Interventions

DEVICE

CRP apheresis

Selective CRP apheresis by use of the "PentraSorb"-CRP

Sponsors & Collaborators

  • Pentracor GmbH

    lead INDUSTRY

Principal Investigators

  • Johannes Dorst, PD Dr. med. · Universitätsklinik Ulm, Abteilung für Neurologie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-28
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Germany

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04417231 on ClinicalTrials.gov